Search details
1.
Efficacy and safety of tepotinib in Asian patients with advanced NSCLC with MET exon 14 skipping enrolled in VISION.
Br J Cancer
; 130(10): 1679-1686, 2024 Jun.
Article
in English
| MEDLINE | ID: mdl-38575731
2.
Randomised Phase 1b/2 trial of tepotinib vs sorafenib in Asian patients with advanced hepatocellular carcinoma with MET overexpression.
Br J Cancer
; 125(2): 200-208, 2021 07.
Article
in English
| MEDLINE | ID: mdl-33972742
3.
Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression.
Br J Cancer
; 125(2): 190-199, 2021 07.
Article
in English
| MEDLINE | ID: mdl-33824476
4.
A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumours.
Br J Cancer
; 124(4): 728-735, 2021 02.
Article
in English
| MEDLINE | ID: mdl-33230210
5.
Correction: Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression.
Br J Cancer
; 125(3): 465, 2021 Aug.
Article
in English
| MEDLINE | ID: mdl-34079081
6.
Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in EGFR-Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT Final Analysis.
Clin Cancer Res
; 29(10): 1879-1886, 2023 05 15.
Article
in English
| MEDLINE | ID: mdl-36971777
7.
Tepotinib Treatment in Patients With MET Exon 14-Skipping Non-Small Cell Lung Cancer: Long-term Follow-up of the VISION Phase 2 Nonrandomized Clinical Trial.
JAMA Oncol
; 9(9): 1260-1266, 2023 09 01.
Article
in English
| MEDLINE | ID: mdl-37270698
8.
Tepotinib: Management of Adverse Events in Patients With MET Exon 14 Skipping Non-Small Cell Lung Cancer.
Clin J Oncol Nurs
; 26(5): 543-551, 2022 09 15.
Article
in English
| MEDLINE | ID: mdl-36108212
9.
Exposure-response analyses for the MET inhibitor tepotinib including patients in the pivotal VISION trial: support for dosage recommendations.
Cancer Chemother Pharmacol
; 90(1): 53-69, 2022 07.
Article
in English
| MEDLINE | ID: mdl-35771259
10.
Safety of MET Tyrosine Kinase Inhibitors in Patients With MET Exon 14 Skipping Non-small Cell Lung Cancer: A Clinical Review.
Clin Lung Cancer
; 23(3): 195-207, 2022 05.
Article
in English
| MEDLINE | ID: mdl-35272955
11.
Safety of Tepotinib in Patients With MET Exon 14 Skipping NSCLC and Recommendations for Management.
Clin Lung Cancer
; 23(4): 320-332, 2022 06.
Article
in English
| MEDLINE | ID: mdl-35466070
12.
Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice.
Clin Cancer Res
; 28(6): 1117-1126, 2022 03 15.
Article
in English
| MEDLINE | ID: mdl-34789481
13.
Anticoagulation with low-molecular-weight heparin (dalteparin) in plasmapheresis therapy: initial experience.
Transfusion
; 46(4): 624-9, 2006 Apr.
Article
in English
| MEDLINE | ID: mdl-16584439
Results
1 -
13
de 13
1
Next >
>>